NSE · SIGACHI · Pharmaceuticals
Sigachi Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹92 Cr with net profit ₹5 Cr — a 5.33% net margin, versus 3.18% the period before.
Shareholding
As of 2026-06-30
- Promoter36.69%
- Public62.05%
- FII1.25%
- DII0%
1,88,986 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.81× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #51 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Sigachi Industries Ltd.(this company) | ₹991 Cr | 129.65 | 1.9 | 6.52% | -17.11% |
AI analysis
AI-generated · google/gemini-2.5-flashSigachi Industries Ltd. is listed with a market capitalization of Rs 956 Cr. The company reported revenue of Rs 508.76 Cr and an EPS of 1.25. Its debt-to-equity ratio stands at 0.26.
Positives
- +The debt-to-equity ratio of 0.26 indicates a relatively low level of debt.
- +The company's book value per share is Rs 14.65.
Negatives
- −Promoter holding has decreased from 48.47% in Mar 2023 to 36.68% in Jun 2026.
- −20.04% of promoter shares are pledged as of June 2026.
- −The company reported a net loss of Rs -100.35 Cr in Jun 2025.
- −The company is currently under ESM Stage 2 surveillance.
- −The quarterly net profit significantly dropped from Rs 10.69 Cr in Sep 2025 to Rs 0.2 Cr in Dec 2025.
Financial Performance
Sigachi Industries Ltd. reported a revenue of Rs 508.76 Cr. The company's EPS is 1.25. Net profit was Rs 7.71 Cr in Mar 2026, after a net loss of Rs -100.35 Cr in Jun 2025. Quarterly revenue has fluctuated, from Rs 139.42 Cr in Dec 2024 to Rs 121.9 Cr in Mar 2026.
Profitability & Returns
The company's Return on Equity (ROE) is 9.8% and its Return on Capital Employed (ROCE) is 6.49%. The PE ratio is 28.1. Net profit for the March 2026 quarter was Rs 7.71 Cr, following a net profit of Rs 0.2 Cr in the December 2025 quarter.
Balance Sheet
The book value per share is Rs 14.65. The debt-to-equity ratio is 0.26, indicating the company's reliance on debt to finance its assets. The trailing twelve-month revenue stands at Rs 508.76 Cr.
Ownership & Pledges
Promoter holding in Sigachi Industries Ltd. is 36.68% as of June 2026. Public shareholding is 62.05%. A significant portion of promoter shares, 20.04%, are pledged.
Regulatory & Surveillance
Sigachi Industries Ltd. is currently under ESM Stage 2 surveillance. This indicates that the stock is subject to enhanced market surveillance measures.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.